Objective: To evaluate the economic feasibility of using bacterial lysates (Broncho-Vaxom) combined with conventional therapy for treating recurrent respiratory tract infections (RRTI) in children. Methods: Cost-benefit analysis was used to calculate the net benefit by comparing the incremental cost and benefit in RRTI children after using bacterial lysates. Expert interviews and questionnaires were conducted for collecting relevant cost and expense parameters. Results: A total of 8 clinicians received the interview and completed the questionnaire

and the collected parameters were analyzed. The results showed that using one course of Broncho- Vaxom could reduce 1. 96 times of RRTI during 6-month follow-up. The incremental cost was about 199. 59 yuan

while with an incremental benefit of 4

601. 98 yuan

which achieved 4

402. 39 yuan in net benefit. This means that for every additional yuan invested

a net benefit of 22. 06 yuan can be obtained. Sensitivity analysis also showed the robustness and reliability. Conclusion: The combined use of bacterial lysates has cost-benefit for the prevention and treatment of RRTI in children. More real-world evidence and data still be needed to supplement and validate the conclusions in the future.